Screener
Spyre Therapeutics, Inc. SYRE Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Spyre Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
FAQ
- What is Spyre Therapeutics, Inc.'s return on equity?
- Spyre Therapeutics, Inc. (SYRE) reported return on equity of -31.1% in Q1 2026.
- How has Spyre Therapeutics, Inc.'s return on equity changed year-over-year?
- Spyre Therapeutics, Inc.'s return on equity increased by 52.7% year-over-year, from -65.8% to -31.1%.
- What is the long-term trend for Spyre Therapeutics, Inc.'s return on equity?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s return on equity has grown at a -20.8% compound annual growth rate (CAGR), from -80.9% to -25.2%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Spyre Therapeutics, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude